PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Phase 2: Versamune^® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC